HepaVue Dx

HepaVue has developed a virtual liver biopsy technology which aims to make diagnosis easier and safer. The team believe that changes in muscle tissue composition can be an indicator of early-stage MASLD. These changes can be detected through existing non-invasive technologies such as CT scans and MRIs. The team will use advanced algorithms to analyse images and identify the subtle changes changes which are difficult to pick up with the human eye but possible through AI.